University of Colorado Cancer Center

COVID-19 recommendations for patients receiving anti-cancer immunotherapies

Newswise — We should all be doing our best to keep from catching COVID-19, if not for ourselves and our loved ones, then to avoid passing the disease to people in high-risk populations – like cancer patients taking chemotherapy, which can lower white blood cell counts and undercut the effectiveness of remaining white blood cells, leaving these patients immunocompromised and less able to fight infections like COVID-19.

But what about cancer patients taking one of the relatively new class of medicines known as immunotherapy? Are these patients similarly at risk? Or, on the other hand, could medicines that activate the immune system in fact protect against COVID-19 infection?

To answer these questions, we reached out to Ryan Weight, DO, MS, investigator at University of Colorado Cancer Center and medical oncologist at the UCHealth Highlands Ranch campus. While working at Thomas Jefferson University, Dr. Weight helped to develop one of the country’s first immunotherapy rapid response teams, defining the emergency response to rare, severe cases of immunotherapy toxicities. He also recently took part in a National Comprehensive Cancer Network (NCCN) panel on immunotherapy side effects, resulting in four pages of updates to the existing guidelines that cancer-care providers use to identify and manage these toxicities.

“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19,” Weight says. However, he cautions that most patients taking anti-cancer immunotherapies including checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) are likely to have other factors that put them at risk, including age and/or factors that accompany the underlying diagnosis of metastatic cancer.

“It is important to understand that there is a fundamental difference between chemotherapy and immunotherapy,” Weight says. “Chemotherapy is a potent immunosuppressive agent, but immunotherapy is in no way  an immunosuppressive agent as we understand it. Many people receiving immunotherapy think the effects will be similar to chemotherapy, and  believe they are at high risk for COVID-19 complications, but as far as we know that’s just not the case.”

The second question is whether anti-cancer immunotherapy could in some way protect against COVID-19. Basically, immunotherapies activate the immune system against cancer, but not all of this extra immune system activity is directed at the disease. This general immune system activation is what sometimes leads to immunotherapy-related side effects. Early reports even made it seem as if immunotherapy could provoke an especially aggressive response against the viral components of annual flu vaccines, implying these medicines may, in fact, lead the immune system to act aggressively against viruses, perhaps including COVID-19.

“But within the last month, a larger study of 162 patients looked at this specifically, and found no increased response to flu vaccines in patients receiving checkpoint inhibitors, so that seems to not be the case,” Weight says.

The timeline of these findings hints at the real challenge: “The checkpoint inhibitor immunotherapies are still  very new,” Weight says. “The first approval was in 2011, but they didn’t hit the mainstream for multiple cancer types until 2015 or 2016. Approvals for immunotherapies to treat many cancer types didn’t come until even later than that.”

In other words, we simply don’t know all the ways anti-cancer immunotherapies might affect a patient’s ability to fight viruses like COVID-19.

“We don’t have any data to support that immunotherapies could reduce a person’s susceptibility to infection. It just hasn’t been studied yet,” Weight says.

So for now, Weight’s recommendation is that patients on immunotherapies don’t count their medicine in the plus or the minus column of COVID-19 risk. 

“It’s not an automatic risk factor like chemotherapy,” Weight says. “However, it’s important to look at all the other factors accompanying a cancer diagnosis like age and measures of frailty. Despite immunotherapy having no likely effect on COVID-19 outcomes, many of these patients will find themselves in the high-risk group for other reasons.”




Filters close

Showing results

110 of 2455
Newswise: Harmful Microbes Found on Sewer Pipe Walls
Released: 6-Jul-2020 6:00 AM EDT
Harmful Microbes Found on Sewer Pipe Walls
Rutgers University-New Brunswick

Can antibiotic-resistant bacteria escape from sewers into waterways and cause a disease outbreak? A new Rutgers study, published in the journal Environmental Science: Water Research & Technology, examined the microbe-laden “biofilms” that cling to sewer walls, and even built a simulated sewer to study the germs that survive within.

Released: 3-Jul-2020 10:25 AM EDT
Lack of lockdown increased COVID-19 deaths in Sweden
University of Virginia Health System

Sweden’s controversial decision not to lock down during COVID-19 produced more deaths and greater healthcare demand than seen in countries with earlier, more stringent interventions, a new analysis finds.

Released: 2-Jul-2020 3:10 PM EDT
Researchers outline adapted health communications principles for the COVID-19 pandemic
CUNY Graduate School of Public Health and Health Policy

The COVID-19 pandemic has introduced unique challenges for public health practitioners and health communicators that warrant an expansion of existing health communication principles to take into consideration.

Released: 2-Jul-2020 1:40 PM EDT
Collectivism drives efforts to reduce the spread of COVID-19
University of Kent

Research from the University of Kent has found that people who adopt a collectivist mindset are more likely to comply with social distancing and hygiene practices to help reduce the spread of COVID-19.

Released: 2-Jul-2020 12:30 PM EDT
Tiny mineral particles are better vehicles for promising gene therapy
University of Wisconsin-Madison

University of Wisconsin–Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination — including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.

Newswise: Newer variant of COVID-19–causing virus dominates global infections
Released: 2-Jul-2020 12:10 PM EDT
Newer variant of COVID-19–causing virus dominates global infections
Los Alamos National Laboratory

Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture.

Newswise: From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
Released: 2-Jul-2020 12:05 PM EDT
From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
La Jolla Institute for Immunology

Two variants of the novel coronavirus (SARS-CoV-2), called G614 and D614, were circulating in mid-March. A new study shows that the G version of the virus has come to dominate cases around the world. They report that this mutation does not make the virus more deadly, but it does help the virus copy itself, resulting in a higher viral load, or "titer," in patients.

Released: 2-Jul-2020 11:50 AM EDT
New Study Explains Potential Causes for “Happy Hypoxia” Condition in COVID-19 Patients
Loyola Medicine

A new research study provides possible explanations for COVID-19 patients who present with extremely low, otherwise life-threatening levels of oxygen, but no signs of dyspnea (difficulty breathing). This new understanding of the condition, known as silent hypoxemia or “happy hypoxia,” could prevent unnecessary intubation and ventilation in patients during the current and expected second wave of coronavirus.

Released: 2-Jul-2020 10:15 AM EDT
Stemming the Spread of Misinformation on Social Media
Association for Psychological Science

New research reported in the journal Psychological Science finds that priming people to think about accuracy could make them more discerning in what they subsequently share on social media.


Showing results

110 of 2455

close
1.49168